Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Smart Eye in conjunction with a directed new issue of shares
Mandate

Vinge advises Smart Eye in conjunction with a directed new issue of shares

October 06, 2020 Capital Markets and Public M&A

Vinge has advised Smart Eye AB in connection with a directed new issue of 1 511 898 new shares at a subscription price of SEK 125 per share, which means that Smart Eye will acquire MSEK 189 prior to issue costs.

The subscription price has been determined through an accelerated book building procedure and corresponds to a discount of 2.9 per cent compared with the volume‑weighted average price on Nasdaq First North Growth Market on 5 October 2020.

Vinge’s team consisted of Anders Strid, Edin Agic and Jacob Benzow.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026